首页> 外文期刊>Blood: The Journal of the American Society of Hematology >HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
【24h】

HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.

机译:CD4 +供体淋巴细胞输注后,病毒感染期间HLA II类上调导致HLA-DP定向的移植物抗宿主病。

获取原文
获取原文并翻译 | 示例
           

摘要

CD8+ T cell-depleted (TCD) donor lymphocyte infusion (DLI) after TCD allogeneic hematopoietic stem cell transplantation (alloSCT) has been associated with a reduced risk of graft-versus-host disease (GVHD) while preserving conversion to donor hematopoiesis and antitumor immunity, providing a rationale for exploring CD4+ T cell-based immunotherapy for hematologic malignancies. Here, we analyzed the clinical course and specificity of T cell immune responses in 2 patients with acute myeloid leukemia (AML) who converted to full-donor chimerism but developed severe acute GVHD after prophylactic CD4+ DLI after 10/10-HLA-matched, but HLA-DPB1-mismatched TCD-alloSCT. Clonal analysis of activated T cells isolated during GVHD demonstrated allo-reactivity exerted by CD4+ T cells directed against patient-mismatched HLA-DPB1 molecules on hematopoietic cells and skin-derived fibroblasts only when cultured under inflammatory conditions. At the time of CD4+ DLI, both patients contained residual patient-derived T cells, including cytomegalovirus (CMV)-specific T cells as a result of CMV reactivations. Once activated by CMV antigens, these CMV-specific T cells could stimulate HLA-DPB1-specific CD4+ T cells, which in turn could target nonhematopoietic tissues in GVHD. In conclusion, our data demonstrate that GVHD after HLA-DPB1-mismatched CD4+ DLI can be mediated by allo-reactive HLA-DPB1-directed CD4+ T cells and that ongoing viral infections inducing HLA class II expression on nonhematopoietic cells may increase the likelihood of GVHD development. This trial is registered at http://www.controlled-trials.com/ISRCTN51398568/LUMC as #51398568.
机译:TCD同种异体造血干细胞移植(alloSCT)后CD8 + T细胞耗竭(TCD)供体淋巴细胞输注(DLI)与降低移植物抗宿主病(GVHD)的风险相关,同时保留了转化为供体造血和抗肿瘤免疫的作用,为探索针对血液恶性肿瘤的基于CD4 + T细胞的免疫疗法提供了理论依据。在这里,我们分析了两名急性髓样白血病(AML)患者的临床过程和特异性,这些患者转化为全供体嵌合体,但在10 / 10-HLA匹配后在预防性CD4 + DLI后发展为严重急性GVHD,但HLA-DPB1不匹配的TCD-alloSCT。对在GVHD期间分离的活化T细胞进行的克隆分析表明,仅当在炎性条件下培养时,针对患者失配的HLA-DPB1分子的CD4 + T细胞才会对造血细胞和皮肤来源的成纤维细胞产生同种反应。在CD4 + DLI发生时,两名患者均含有残留的患者衍生T细胞,包括巨细胞病毒(CMV)特异性T细胞,这是CMV重新激活的结果。一旦被CMV抗原激活,这些CMV特异性T细胞就可以刺激HLA-DPB1特异性CD4 + T细胞,进而可以靶向GVHD中的非造血组织。总之,我们的数据表明,HLA-DPB1不匹配的CD4 + DLI后的GVHD可以由同种反应性HLA-DPB1定向的CD4 + T细胞介导,正在进行的病毒感染诱导非造血细胞上HLA II类表达,可能会增加GVHD的可能性发展。该试用版已在http://www.control-trials.com/ISRCTN51398568/LUMC上注册为#51398568。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号